Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 20/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916991 | 1.00 | GALR3 (1.00) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8273294 | 1.00 | GALR3 (1.00) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL918247 | 0.93 | GALR3 (0.87) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL3240615 | 0.93 | GALR3 (0.87) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL915968 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL915969 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL916679 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL916677 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8164607 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL6904884 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959982-B1 | METHODS AND COMPOSITIONS FOR PREVENTING AND/OR TREATING PANCREATITIS | FLINDERS TECHNOLOGIES PTY LTD (AU) | 2012-08-08 | — | — | EP | claimed |
| WO-2004014855-A1 | PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| US-20130189314-A1 | ENTERIC-COATED HT-2157 COMPOSITIONS AND METHODS OF THEIR USE | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-07-25 | — | — | US | disclosed |
| US-8277842-B1 | Enteric-coated HT-2157 compositions and methods of their use | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2012-10-02 | — | — | US | disclosed |
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| EP-2241316-A1 | Indolone compounds useful to treat cognitive impairment | Helicon Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1957067-B1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | HELICON THERAPEUTICS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-07-15 | — | — | US | disclosed |
| US-20100028839-A1 | METHODS AND SYSTEMS FOR EVALUATING MEMORY AGENTS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-02-04 | — | — | US | disclosed |
| US-20050192337-A1 | Processes and polymorphs of diaryl-indolone galr3 antagonists | H. LUNDBECK A/S (DK) | 2005-09-01 | — | — | US | disclosed |
| US-20050192337-A1 | Processes and polymorphs of diaryl-indolone galr3 antagonists | H. LUNDBECK A/S (DK) | 2005-09-01 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2004-05-27 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| WO-2004014855-A1 | PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014855-A1 | PROCESSES AND POLYMORPHS OF DIARYL-INDOLONE GALR3 ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | CHAT, AANAT, TPH2 | GALR3 450/4885HTR4 12/4885DRD5 351/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 30/4885DRD5 639/4885 |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885DRD5 399/4885 |
| US-20050192337-A1 | Processes and polymorphs of diaryl-indolone galr3 antagonists | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 266/4885DRD5 1739/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 17/4885DRD5 350/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 24/4885DRD5 534/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 214/4885DRD5 1740/4885 |
| US-20130189314-A1 | ENTERIC-COATED HT-2157 COMPOSITIONS AND METHODS OF THEIR USE | HTR7, HTR5A, HNMT | GALR3 875/4885HTR4 17/4885DRD5 114/4885 |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | GALR3 1/4885HTR4 30/4885DRD5 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.